Pharmaceutical Technology

NOVEMBER 11, 2022

The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. It is indicated as a booster in people of this age group who were earlier inoculated with a Covid-19 vaccine.

Vaccination 246

Vaccination Vaccine Immune Response Protein 246

Pharmaceutical Technology

AUGUST 5, 2022

As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. It is ultra-rare,” says Jesús Rodriguez Requena, PhD, associate professor in the Department of Medicine at the University of Santiago de Compostela. And then comes the question of the right target.

Drugs 299

Drugs Protein Vaccination Vaccine 299

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccination 277

Vaccination Vaccine Immune Response Antibody 277

Pharmaceutical Technology

AUGUST 2, 2022

The Health Emergency Preparedness and Response Authority (HERA) of the European Commission (EC) has entered a co-procurement framework contract for HIPRA HUMAN HEALTH’s bivalent recombinant protein Covid-19 vaccine. billion doses of Covid-19 vaccines. An increase in vaccination and boosting is essential over the coming months.

Vaccination 162

Vaccination Vaccine Protein Medicine 162

Pharmaceutical Technology

SEPTEMBER 14, 2022

Novavax and Serum Institute of India (SII) have reported that the former’s Covid-19 vaccine, NVX-CoV2373, has received full product registration from the South African Health Products Regulatory Authority (SAHPRA), with conditions. The vaccine showed efficacy, with an encouraging safety and tolerability profile, in the trials. .

Vaccination 147

Vaccination Vaccine Clinical Trials Clinical Trials 147

Medical Xpress

FEBRUARY 16, 2023

An adenovirus serotype 26 respiratory syncytial virus (RSV) vector encoding a prefusion F (preF) protein (Ad26.RSV.preF) RSV.preF) in combination with RSV preF protein is immunogenic and prevents RSV-mediated lower respiratory tract disease in older adults, according to a study published in the Feb.

Protein 98

Protein Vaccination Vaccine Medicine 98

Medical Xpress

FEBRUARY 22, 2023

Medicines that are based on mRNAs and proteins—particularly vaccines and antibodies—are time-intensive and costly to make. The challenge is in producing the necessary mRNAs and proteins in large enough amounts at low cost.

Protein 75

Protein Medicine Production Antibody 75

Pharmaceutical Technology

MAY 29, 2023

Novavax has received positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for full marketing authorisation (MA) of its Covid vaccine, Nuvaxovid (NVX-CoV2373) , in the European Union (EU). The safety and efficacy of Nuvaxovid was evaluated as a primary series.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

Pharmaceutical Technology

SEPTEMBER 2, 2022

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting expanded conditional marketing authorization (CMA) for Novavax ’s Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), as a booster in adults aged 18 years and above.

Vaccination 147

Vaccination Vaccine Trials Clinical Trials 147

Scienmag

NOVEMBER 16, 2021

Despite great progress with SARS-CoV-2 vaccines, there is still a need to accelerate vaccination in low- and middle-income countries and a need for more effective vaccine strategies in older adults, who tend to have weaker immune responses to vaccination.

Protein 84

Protein Vaccination Vaccine Immune Response 84

Pharma Mirror

SEPTEMBER 11, 2022

Bandung, W Java, Indonesia, PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing of IndoVac, a Covid-19 vaccine brand it has developed since November 2021.

Vaccination 130

Vaccination Vaccine Clinical Trials Clinical Trials 130

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Pharmaceutical Technology

OCTOBER 3, 2022

Indonesia has granted Emergency Use Authorization (EUA) for the patent-free Covid-19 vaccine, IndoVac, developed by the Texas Children’s Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine, US. PT Bio Farma will manufacture 20 million doses of the vaccine this year.

Vaccination 130

Vaccination Vaccine Development Production 130

Pharmaceutical Technology

OCTOBER 7, 2024

mRNA-based vaccines, which instruct cells to produce proteins that can prevent or treat disease, show great promise in precision medicine.

Licensing 130

Licensing Licensing Protein Vaccination 130

Pharmaceutical Technology

AUGUST 17, 2022

These programmes will include therapies and vaccines in infectious disease and oncology areas. oRNA molecules have been demonstrated to possess increased stability in vivo compared to linear mRNA and can potentially create more quantities of therapeutic proteins within the body. .

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccination 162

Vaccination Vaccine Antibody Development 162

Pharmaceutical Technology

AUGUST 23, 2022

5-adapted bivalent vaccine for Covid-19 in people aged 12 years and above. 1-adapted vaccine. The FDA also sought the vaccine’s pre-clinical and manufacturing data for addressing the SARS-CoV-2 virus’ evolution. 5-adapted bivalent vaccine will be made readily available for shipping. 5 variant spike protein.

Vaccination 130

Vaccination Vaccine Gene Therapy Protein 130

Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

Pharmaceutical Technology

APRIL 27, 2023

Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement. New investors included the Redmile Group, the Abu Dhabi Growth Fund (ADG), Exor, Invus, Moore Strategic Ventures, the iGlobe Platinum Fund Group and Casdin Capital.

RNA 130

RNA Medicine Gene Therapy Gene 130

pharmaphorum

JULY 18, 2022

MBA, managing director at CanSino Biologics Europe, tells us about Convidecia, a single dose SARS-CoV-2 vaccine offered as an injectable and inhalant that allows ease of storage, an alternative option for individuals with needle phobias, and robust elongated CD4 and CD8 cellular response. Morgon, PharmD, LL.M,

Vaccination 138

Vaccination Vaccine Development Immune Response 138

pharmaphorum

SEPTEMBER 6, 2022

The NHS is moving to the next phase of its SARS-CoV-2 vaccination programme, following health secretary Steve Barclay’s acceptance of advice from the Joint Committee on Vaccination and Immunisation (JCVI) to go ahead with rollout of Pfizer’s bivalent 30mg booster shot this week. 1 (15mg) spike protein. million of 31.4

Vaccination 98

Vaccination Vaccine Protein Medicine 98

pharmaphorum

SEPTEMBER 14, 2020

AstraZeneca has resumed UK trials for its coronavirus vaccine, after the country’s medicines regulator gave the all-clear following a safety scare. A UK safety committee has concluded its investigations and recommended to the country’s Medicines and Healthcare products Regulatory Agency (MHRA) that trials are safe to resume.

Vaccination 104

Vaccination Vaccine Trials Protein 104

Scienmag

APRIL 1, 2021

Blanc, Michael Gecht, Roberto Covino and Gerhard Hummer A new, detailed model of the surface of the SARS-CoV-2 spike protein reveals previously unknown vulnerabilities that could inform development of vaccines. Mateusz […].

Protein 81

Protein Vaccination Vaccine Development 81

Pharmaceutical Technology

DECEMBER 16, 2022

Novel therapeutics and vaccines for malaria. Novartis and the non-profit Medicines for Malaria Venture (MMV) announced plans to collaborate on a Phase III study of a novel ganaplacide/lumefantrine-SDF combination for adults and children. Apart from vaccines, other approaches for preventing malaria are also being studied.

Development 264

Development Drugs Vaccination Vaccine 264

Scienmag

MARCH 1, 2022

The SARS-CoV-2 virus is continuously evolving and structural changes to the virus may impact the efficacy of antibody therapies and vaccines.

Protein 83

Protein Vaccination Vaccine Antibody 83

pharmaphorum

OCTOBER 2, 2020

European regulators have started a first ‘rolling review’ of a COVID-19 vaccine, which is being developed by AstraZeneca in collaboration with the University of Oxford. But this does not mean that the CHMP is ready to make a conclusion on the safety and efficacy of the vaccine.

Regulation 105

Regulation Vaccination Vaccine Protein 105

XTalks

DECEMBER 20, 2021

The World Health Organization (WHO) has backed Novavax’s COVID-19 vaccine, Covovax (NVX-CoV2373), by granting it an emergency use listing (EUL). The company is awaiting on authorization of its vaccine from regulatory health bodies around the world, including the US Food and Drug Administration (FDA) and Health Canada.

Vaccination 96

Vaccination Vaccine Protein Manufacturing 96

pharmaphorum

NOVEMBER 12, 2020

The European Union has ordered 300 million doses of BioNTech/Pfizer’s COVID-19 vaccine following this week’s landmark announcement that it was effective in more than 90% of patients. Vaccine doses for Europe will be produced in BioNTech’s German manufacturing sites, as well as in Pfizer’s manufacturing site in Belgium.

Vaccination 105

Vaccination Vaccine Manufacturing Regulation 105

Scienmag

MAY 24, 2022

New experiments conducted in mice add to mounting evidence in opposition to a popular claim that COVID-19 vaccination during early pregnancy may cause birth defects or fetal growth problems. The study also counters claims that COVID-19 vaccines reduce fertility through their effects on the protein syncytin-1.

Vaccination 86

Vaccination Vaccine Protein Medicine 86

pharmaphorum

SEPTEMBER 17, 2020

US medical experts are reportedly concerned that a neurological side effect picked up in AstraZeneca’s closely-watched COVID-19 vaccine trial could compromise the whole project, as the FDA weighs whether to give the go ahead for US studies to resume. Nath told CNN: “The highest levels of NIH are very concerned.

Vaccination 105

Vaccination Vaccine Trials Medicine 105

pharmaphorum

SEPTEMBER 2, 2022

The EMA’s human medicines committee (CHMP) has recommended authorisation of two COVID-19 vaccines from Moderna and Pfizer/BioNTech that include sequences coding for Omicron spike protein as booster shots. The FDA has just authorised vaccines from the two companies that will specifically target the BA.4

Vaccination 103

Vaccination Vaccine Protein Regulation 103

Scienmag

APRIL 22, 2021

In February, the researchers introduced […].

Production 84

Production Vaccination Vaccine Protein 84

XTalks

JUNE 5, 2023

Pfizer has announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has received approval from the US Food and Drug Administration (FDA). Abrysvo, the bivalent RSV prefusion F (RSVpreF) vaccine, is intended for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

XTalks

OCTOBER 12, 2021

Last week, a study that “stumbled upon” a vaccine for rheumatoid arthritis (RA) was published in the Proceedings of the National Academy of Sciences. The experimental arthritis vaccine was developed by researchers at the University of Toledo (UToledo) and is a major breakthrough for rheumatoid arthritis and other autoimmune diseases as well.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

Pfizer

SEPTEMBER 28, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted 5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age. Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted 5-adapted bivalent vaccine. 5) AUTHORIZED USES .

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

pharmaphorum

JUNE 9, 2022

Moderna’s new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company’s original Spikevax shot in a head-to-head clinical trial. It has predicted sales of COVID-19 vaccines will be around $21 billion this year. Three-month data will be reported later this summer.

Vaccination 105

Vaccination Vaccine Containment Clinical Trials 105

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccination 105

Vaccination Vaccine Research Immune Response 105